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Reinterpretation, reclassification, and its
downstream effects: challenges for clinical
laboratory geneticists
Julia El Mecky1,2*† , Lennart Johansson1†, Mirjam Plantinga1, Angela Fenwick2, Anneke Lucassen2,
Trijnie Dijkhuizen1, Annemieke van der Hout1, Kate Lyle2 and Irene van Langen1
Abstract
Background: In recent years, the amount of genomic data produced in clinical genetics services has increased
significantly due to the advent of next-generation sequencing. This influx of genomic information leads to
continuous changes in knowledge on how genetic variants relate to hereditary disease. These changes can have
important consequences for patients who have had genetic testing in the past, as new information may affect their
clinical management. When and how patients should be recontacted after new genetic information becomes
available has been investigated extensively. However, the issue of how to handle the changing nature of genetic
information remains underexplored in a laboratory setting, despite it being the first stage at which changes in
genetic data are identified and managed.
Methods: The authors organized a 7-day online focus group discussion. Fifteen clinical laboratory geneticists took
part. All (nine) Dutch clinical molecular genetics diagnostic laboratories were represented.
Results: Laboratories in our study reinterpret genetic variants reactively, e.g. at the request of a clinician or
following identification of a previously classified variant in a new patient. Participants currently deemed active,
periodic reinterpretation to be unfeasible and opinions differed on whether it is desirable, particularly regarding
patient autonomy and the main responsibilities of the laboratory. The efficacy of reinterpretation was questioned in
the presence of other strategies, such as reanalysis and resequencing of DNA. Despite absence of formal policy
regarding when to issue a new report for clinicians due to reclassified genetic data, participants indicated similar
practice across all laboratories. However, practice differed significantly between laboratory geneticists regarding the
reporting of VUS reclassifications.
Conclusion: Based on the results, the authors formulated five challenges needing to be addressed in future
laboratory guidelines: 1. Should active reinterpretation of variants be conducted by the laboratory as a routine
practice? 2. How does reinterpretation initiated by the laboratory relate to patient expectations and consent?
3. When should reinterpreted data be considered clinically significant and communicated from laboratory to clinician?
4. Should reinterpretation, reanalysis or a new test be conducted? 5. How are reclassifications perceived and how
might this affect laboratory practice?
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Introduction
In recent years, the amount of genomic data produced
in clinical genetics services has increased significantly
due to the advent of next-generation sequencing. This
influx of genomic information not only leads to an in-
creased diagnostic yield, but also results in a continuous
redrawing of connections between genetic variants and
genetic conditions. This is demonstrated by the fact that
many variants have been reinterpreted and reclassified
(Table 1) to either more or less pathogenic than previ-
ously thought [28] and new genes and variants are con-
tinuously identified to potentially play a role in the
development of medical conditions [2, 16, 19, 26]. The
changing nature of genetic knowledge can have import-
ant consequences for patients who have had genetic test-
ing in the past, as new information on genetic variants
may affect their clinical management. It has been investi-
gated extensively when and how patients need to be
recontacted when new genetic information becomes
available, both in clinical and in research contexts ([5,
14, 15, 21]; Carrieri et al. 2019 [29]; David et al. 2019 [7,
12, 24];). However, the issue of how to handle the chan-
ging nature of genetic information in a laboratory setting
is significantly underexplored [33], despite it being the
first stage at which changes in genetic information are
identified and managed. Research and guidelines that in-
clude laboratory geneticists’ perspectives on this topic
focus on what to do after new genetic information has
been generated. This focus omits critical questions re-
garding the process before and during which new infor-
mation is identified: If, when, and how often should
available evidence on the pathogenicity of genetic vari-
ants be reinterpreted by the laboratory after initial test
results have been given to patients?; Who is responsible
for making the decision to conduct reinterpretation?;
And in which cases has knowledge around genetic vari-
ants changed sufficiently for a laboratory to reclassify
them and issue a new report, informing clinicians of this
change? Therefore, whilst acknowledging that recontact
is an important topic within the laboratory context [29],
this paper primarily focuses on laboratory practice
around reinterpretation and reclassification.
To our knowledge, this is the first qualitative inquiry
into perspectives of clinical laboratory geneticists regard-
ing their current and desired future practice in the con-
text of reinterpretation and reclassification of genetic
variants. Based upon a week-long online focus group
discussion with clinical laboratory geneticists represent-
ing all (nine) Dutch clinical molecular genetics labora-
tories, the authors identify key issues and concerns that
laboratory geneticists may contend with in practice, in
order to scope out challenging themes within an un-
charted territory that should be further addressed in
guidelines, research, ethical considerations, and practice.
Methods
We invited the heads of department of all (n = 9) clinical
molecular genetics diagnostic laboratories in the
Netherlands to participate in a 7-day online focus group
discussion in September 2017, hosted on the platform
focusgroupit.com. We requested the heads of depart-
ment to extend our invitation to all clinical laboratory
geneticists in their laboratory. All laboratories were non-
commercial, as, by law, only certified, non-commercial
molecular genetics laboratories are allowed to conduct
clinical genetic testing in The Netherlands. All labora-
tories were affiliated with clinical genetics departments
in academic hospitals, which are responsible for all clin-
ical genetics diagnostics conducted in The Netherlands
and whose services in genetic testing and counseling are
covered by public healthcare insurance. Fifteen clinical
laboratory geneticists decided to participate in the dis-
cussion. All molecular genetics diagnostic laboratories in
the Netherlands were represented in the sample (1–3
participants per laboratory). Each participant was allo-
cated an alias with the aim to remain anonymous within
the group.
A semi-structured approach to the facilitation of the
discussion was chosen, so that new themes could emerge
through discussion by and between participants. The
discussion questions posed by the authors served to
guide the discussion, simultaneously leaving room for
participants to bring in their own themes and issues. A
topic list consisting of questions and propositions (see
Additional file 1) was composed to identify current and
desired practice around reinterpretation and reclassifica-
tion of variants, as well as laboratory communication of
reinterpreted and reclassified data to clinicians. The
topic list was designed by the research group, in which
laboratory geneticists were represented, based on exist-
ing literature and clinical experience. At the beginning
of each of the first 5 days of the online discussion, a new
topic was posted on the platform. The topic list was ad-
justed iteratively as the discussion progressed, i.e.
Table 1 Key definitions
Reinterpretation
Re-evaluation of genetic variants that have been analyzed
and interpreted in the past, in order to assess whether the initial
classification is still correct or should be changed in light of new
information. This may result in an updated and modified report on the
data in question by the laboratory to the clinician.
Reclassification
Assigning a different pathogenicity to a variant that has been classified
in the past (e.g. from benign to likely pathogenic). In this article, we
refer to the classification system described by Richards et al. [27] in
which class 1 is benign; class 2 is likely benign; class 3 is variant of
uncertain significance; class 4 is likely pathogenic; class 5 is pathogenic.
Adapted from Carrieri et al. 2018
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questions and propositions were adapted based on
themes that came up in discussion on previous days.
Participants were invited to log in one or multiple
times per day at their own convenience (asynchronous
format), in order to respond to the questions posed and
to each other’s responses. In the final 2 days of the dis-
cussion, no new topics were posted and participants
were encouraged to respond, if they had not yet done so,
to previous topics or to continue on-going discussion.
The discussion was moderated by JM, a medical anthro-
pologist, who asked follow up questions to each re-
sponse. One laboratory geneticist, TD, and one clinical
geneticist, IL, who were not participants, followed the
discussion and advised JM on moderation and follow-up
questions. After 1 week, the forum was closed and each
participant received a voucher worth €25.
Thematic analysis [6] was conducted inductively with
the help of NVIVO software by QSR International (ver-
sion 11), focusing on challenges regarding reinterpret-
ation and reclassification. JM and LJ, a bioinformatician
with a background in ethics, coded the data independ-
ently. Subsequently all coding was compared and dis-
crepancies were discussed until agreement was reached.
Citations included in this paper were translated from
Dutch to English by JM and LJ.
In an effort to be of most use to broader academic,
policy, guideline, and practice discussions regarding
reinterpretation and reclassification, we combined the
results and discussion sections. This allowed for direct
reflection on the findings in the context of current litera-
ture available on reinterpretation and reclassification.
Results and discussion
During the focus group discussion, participants described
their current and desired practice, whilst identifying issues
regarding reinterpretation and reclassification. Further
challenges came to light through discrepant practices
described by participants. Based on these accounts, the
authors identified the following five challenges.
Should active reinterpretation of variants be conducted
by the laboratory as a routine practice?
Participants indicated that in current Dutch clinical ge-
netics laboratory practice, reinterpretation mainly takes
place reactively, i.e. in response to an event (Table 2).
There is no routine practice in Dutch laboratories of ac-
tively reviewing the latest available evidence on variants.
In terms of possible, future implementation of active,
periodic reinterpretation, a distinction can be made be-
tween what is desirable and feasible laboratory practice.
Desirability
Active, periodic reinterpretation of variants could be
an important strategy for ensuring patients are alerted
to changing evidence surrounding genetic variants.
Participants indicated that rare variants in particular
are currently less likely to be reinterpreted, as the
chance that they are detected in other patients is rela-
tively small. One laboratory was investigating ways to
implement active, periodic reinterpretation of all VUS
in their in-house database. However, active, periodic
reinterpretation was not unequivocally considered a
desirable practice by participants; they expressed
concerns whether such reinterpretation could be
adequately understood and consented to by patients
during the process of genetic counseling (see
Methods). Active reinterpretation of patient data was
not seen by participants as a responsibility of the
laboratory, as the laboratory’s aim, similar to other
medical fields, was seen as providing service at
request, rather than actively initiating services.
Table 2 Types of reinterpretation illustrated by fictional casesa
Reactive reinterpretation
The laboratory conducts reinterpretation of previously identified
variants due to an external trigger. This can be a) a request from
patient or clinician or b) identifying a previously classified variant in a
new patient
Case a. Reactive reinterpretation upon request:
Ms. P’s 10 year old child, A, has learning difficulties. A is referred to Dr. F,
a clinical geneticist, and a genetic test is performed, identifying a variant
of uncertain significance (VUS/class 3) in FOXP2. Dr. F discusses this result
with Ms. P, explaining that a genetic variant has been identified that
could possibly be the cause for A’s learning difficulties, but could equally
likely play no part. Dr. F recommends that Ms. P return to the clinic in a
few years to enquire whether new information is available. Ms. P
contacts Dr. F two years after the initial results, who in turn contacts the
laboratory to inform about the current state of affairs regarding the
FOXP2 VUS. The laboratory reinterprets the variant and informs Dr. F
that the variant can now be reclassified as class 1 benign and therefore
non-causal for A’s symptoms.
Case b. Reactive reinterpretation upon identification of variant in new
patient:
Mr. C is diagnosed with colorectal cancer and is referred for genetic
testing. A likely pathogenic variant (LP/class 4) in MSH6 is identified.
Three years later a different patient, Ms. L, unrelated to Mr. C, is referred
to the clinic due to colorectal cancer. A genetic test is performed and the
same MSH6 variant is identified. Review of the evidence now suggests it
is a pathogenic (class 5) variant and the classification in Mr. C’s case is
also changed to pathogenic. A new report informing of this change is
issued to Mr C’s clinician.
Active reinterpretation
The laboratory initiates reinterpretation of previously identified
variants, without an external trigger
Case c. Active reinterpretation:
A molecular genetics laboratory decides to biannually reinterpret all
variants that are classified as VUS in their database. When new evidence
is sufficient, these variants are reclassified and their new classification is
registered in the laboratory’s database. Clinicians whose patients have
been identified to carry these variants are informed of the
reclassifications. All patients whose genetic testing is conducted through
this laboratory are informed of this policy at their clinical consultations.
aThe fictional cases listed in this table were not used during the focus group
discussion, but rather serve to clarify different possible reinterpretation
scenarios for the purpose of this paper
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Therefore the main responsibility to initiate reinter-
pretation of genetic data was considered to lie with
patients (in tandem with their clinicians).
“We are service-oriented, in other words: at the request
of the patient.” (Participant 11) “In my opinion it’s
comparable to a doctor: they don’t re-evaluate their
pictures and files every year either to see if there is any
new information. (Participant 3).
Feasibility
In terms of feasibility, the main factor impeding active,
periodic reinterpretation according to participants was
work load. Such a procedure was currently deemed to be
financially and logistically unachievable, as the process of
reinterpretation was seen as laborious and unamenable to
complete automation. Participants noted that since differ-
ent conditions require different kinds of evidence to clas-
sify variants as either benign or pathogenic, combined
with the fact that laboratory geneticists differed in what
they considered as adequate evidence for (re) classifica-
tion, automating reinterpretation and reclassification was
considered challenging.
“As mentioned by many [others], automation is hard,
because the correct application of data present in
databases and literature is almost impossible to
interpret in silico. For this, you’ll always need
humans.” (Participant 2).
“Active [reinterpretation] of data is currently not
feasible in terms of work [load]. ( …) Possibly, if [these
processes] are more automated in the future, there will
be more possibilities to do this (and to want [to do
this]).” (Participant 3)
Several guidelines indicate that laboratories do not have
any responsibility to routinely reinterpret genetic data, so
as not to be overloaded or compromised in other duties
related to patient care [4, 18]. However, we propose that
active, periodic reinterpretation does not necessarily need
to be conceptualized in an all-or-nothing way: a middle
ground may also be feasible. Actively reclassifying only
those variants for which clear, new evidence is present re-
garding a pathogenic (or benign) effect could benefit some
patients, without leading to extensive database and litera-
ture searches. In terms of bioinformatics, this would mean
that the threshold to flag a variant for possible reclassifica-
tion is set high. Commercial companies exist that provide
active, periodic reclassification [22]. Tools such as Inter-
Var [17], which use a formalized protocol, could possibly
aid automation of the classification process. Furthermore,
an infrastructure in which classifications and variant
frequencies are automatically shared between laboratories
[24], as well as an infrastructure to alert clinicians or la-
boratory geneticists to updated classifications, as discussed
by Aronson et al. [1], could aid management of reclassified
variants. The field of artificial intelligence could offer in-
teresting opportunities in this context. In terms of com-
paring genetics services to other medical services which
tend to offer services at request, rather than actively initi-
ating them, it is important to note that genetic data differs
from most other kinds of medical data, as it is constant
throughout a patient’s life; only its analysis and interpret-
ation changes. As the laboratory knows more about
current variant classifications than clinicians, let alone pa-
tients [11], it is important to explore to what degree la-
boratories could and should have systems in place for
systematic reinterpretation. Many variants, especially re-
lating to patients with rare diseases and patients from an-
cestries underrepresented in the genomic evidence base
[5], are found infrequently on a global level. Importantly,
not conducting active, periodic reinterpretation might re-
sult in an inequitable service where some patients more
than others are left unaware of new evidence, thereby
posing an injustice issue.
How does reinterpretation initiated by the laboratory
relate to patient expectations and consent?
Participants indicated that, in current Dutch laboratory
practice, variant reinterpretation is initiated by labora-
tory geneticists during the analysis of new patients, with-
out updated consent from previous patients with the
same variants (Table 2, case b). Concerns existed among
laboratory geneticists regarding the autonomy of these
patients, as well as the durability of consent. Even if the
possibility of reinterpretation was discussed during initial
counseling, participants felt unclear about patients’ abi-
lity to fathom that consent regarding reinterpretation of
their genetic information is given for an undetermined
period of time. This may result in unexpected and
possibly, in that moment, unwanted recontact.
“When the same VUS is detected in a new patient, it
will routinely be evaluated again. The question
whether patients desire [reinterpretation] does not play
a role in my decision making. [ …] [Because] the
patient is informed about this possibility and also gave
consent. However, I do wonder if they realize that they
can be contacted two years later.” (Participant 9).
Concerns particularly existed regarding patient expec-
tations, understanding, and wishes in discussions regard-
ing active reinterpretation.
“Very rarely you have to send a corrected letter to the
first patient, who thinks his/her [DNA] examination
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has been concluded and often is not looking for [new
information]. Therefore, you should not be doing this
routinely for each detected variant.” (Participant 6).
“It seems to me that it’s of main importance that the
patient wants [active, routine reinterpretation]!”
(Participant 9).
We pose that for laboratory geneticists, an important
conceptual difference between active and reactive re-
interpretation might be the generation of new informa-
tion (active reinterpretation) versus reporting of
information that has already been generated (reactive re-
interpretation and reclassification following identifica-
tion of a previously detected variant in a new patient).
They may feel a stronger moral responsibility to act on
information that has already been generated, as in the
case of reactive reinterpretation following identification
of a previously detected variant in a new patient, in com-
parison to the moral responsibility to take the initiative
in generating new information. This may explain why
more hesitance was expressed regarding respecting pa-
tient autonomy in the context of active reinterpretation
in comparison with reactive reinterpretation. However,
from the perspective of the patient, this conceptual dif-
ference may not exist. For the patient, being recontacted
based on reactive reinterpretation initiated by the
laboratory does not differ from being recontacted based
on active reinterpretation initiated by the laboratory.
Therefore, implementing active, periodic reinterpretation
does not diverge from current practice, in terms of the
possible negative consequence of unexpected recontact
from a patient perspective, except that it would likely
occur on a larger scale.
It is important not to alleviate the moral distress around
patient autonomy as expressed by laboratory geneticists by
automatically precluding active, periodic reinterpretation.
Rather, these concerns should be addressed through empir-
ical inquiry into what general patient expectations and un-
derstanding are regarding reinterpretation of their genetic
data and through investigation of proper means of counsel-
ing and consent suitable for the genomic era. This could in-
clude dynamic consent, allowing patients to halt or continue
active reinterpretation of their data at their preference; a lar-
ger emphasis during pre- and post-test counseling on the
possibility of change in genetic knowledge and its implica-
tions for (family) medical management; and the exploration
of technological infrastructures that allow the possibility, if
desired by patients, of not reinterpreting or reclassifying
their data. Particularly, an important question is whether it
is good practice to give patients the opportunity to broadly
opt out of potentially medically actionable information, as
this is a complex decision regarding information that cannot
be envisaged accurately by patients at the time. A potential
additional problem with this approach is that different fam-
ily members carrying the same variant(s) might then give
different kinds of consent, leading to new reports being is-
sued for some family members in case of variant reclassifica-
tion, but not for others. This may give rise to difficult and
tense family situations, as well as different medical treatment
and screening protocols within one family, begging the
question whether patient choice in this context is feasible
and desirable in practice.
When should reinterpreted data be considered clinically
significant and communicated from laboratory to
clinician?
Participants pointed out that when patients and their cli-
nicians ask a laboratory for reinterpretation of a previ-
ously reported variant, the laboratory communicates any
new information or lack thereof to the clinician of the
patient in question.
In contrast, participants indicated that when a variant
is reclassified without prior inquiry by a patient or their
clinician (e.g. when the variant is found in a new patient
and reclassified for all individuals carrying this variant),
communication of this new information from laboratory
to clinician does not occur by default. Whether a reclas-
sification potentially affects a patient’s (or their family’s)
clinical management, i.e. its clinical significance, is the
underlying principle of Dutch laboratories’ practices and
decisions related to recontacting clinicians. Our focus
group discussion suggests that laboratory geneticists
might often feel the clinician is responsible for establish-
ing which reclassified variants are clinically significant
enough to warrant recontact.
“Communicating [reclassified variants] to the
clinician seems to me [ …] to precede over the
clarity of medical relevance. The latter is namely
the eventual responsibility of the medical specialist.”
(Participant 9).
In practice, however, laboratory geneticists also make
decisions on this matter by deciding which reclassifica-
tions are of clinical significance and therefore need to be
communicated to clinicians. Despite absence of formal
policy, participants indicated that it is standard practice to
communicate the following reclassifications to clinicians,
in case reinterpretation took place without request by pa-
tient or clinician: any variant that is upgraded to (likely)
pathogenic (e.g. likely benign to likely pathogenic), as well
as (likely) pathogenic variants that are downgraded (e.g.
pathogenic to VUS) (Table 3). An exception constitutes
pathogenic variants that are downgraded to likely patho-
genic. Often, these reclassifications are not reported to cli-
nicians, as they are not expected to affect clinical
management. However, practice differs most significantly
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for VUS that are downgraded to (likely) benign or vice
versa: some laboratory geneticists do, whilst others do not
communicate these reclassifications to clinicians, as
laboratory geneticists differ in whether they consider these
reclassifications as clinically significant.
Some laboratory geneticists argued that when a VUS is
reclassified to a benign or likely benign variant, this does
not merit recontact with the referring clinician, as it
would not affect patients’ medical management. This is
in line with ACMG recommendations that VUS should
not be used in clinical decision-making [27]. However,
one participant observed that clinicians often communi-
cate VUS to patients as possibly causative of their clinical
symptoms, when they are detected and reported in the
original laboratory report.
“In case of a reclassification from (…) [class] 3 to 2/1,
in principle no [new lab report] will follow, because it
doesn’t change [clinical] management.” (Participant 8).
“I do report a reclassification from [class] 3 to 1/2 [to
the referring clinician] in case I come across it. It
really depends on the condition. I can imagine that for
onco [genetics], for example, it won’t change [clinical]
management, but for many other conditions a class 3
[variant] is often counseled as possibly causative. If
you then know for certain that it’s not pathogenic, I
think you can report it.” (Participant 7).
Vos et al. [34] and Solomon et al. [31], among others,
have documented the degree to which detected VUS
that are communicated to patients as potentially causa-
tive of their phenotype can have a significant emotional
impact on patients and their families. Furthermore, in
some cases, a VUS might be tracked within families to
see whether it segregates with the clinical phenotype.
Therefore, we suggest that VUS cannot be seen as
entities outside of clinical decision-making. In some
cases, such as when VUS have previously been commu-
nicated to patients as highly suspicious in causing their
symptoms, it may be important for the laboratory to re-
port down-classifications of VUS to clinicians. As such,
we propose that down-classifications of VUS should not
be excluded by default, in contrast to what Chisholm
et al. [9] suggest with their proposed workflow for re-
interpretation of variants.
Should reinterpretation, reanalysis or a new test be
conducted?
In certain cases, participants believed that reanalysis may
prove to be diagnostically more effective than reinter-
pretation. Reanalysis involves using a patient’s existing
raw data (that has been generated as a result of genetic
sequencing in the past, e.g. whole exome sequencing) in
order to analyze all genes currently associated with the
patient’s condition or symptoms, without having to con-
duct a new genetic test. This includes genes that were
not analyzed previously, as a connection with the pa-
tient’s condition was not known at the time. Approaches
that include novel associated genes have demonstrated
the potential to increase diagnostic yield ([30]; Wright
et al., [35]). Furthermore, updated workflows and
changes in resources (e.g. utilization of a new reference
genome [10] or the addition of CNV detection [25]) can
sometimes identify variants that previously went un-
noticed. In light of fast-changing techniques, improved
coverage, decreasing costs, and growing knowledge, it
might even be more efficient to request a completely
new test (i.e. resequencing of DNA), based on the latest
laboratory and analysis standards, rather than perform-
ing reinterpretation or reanalysis of existing data.
“I believe that the patient (in consultation with the
clinician) can actively request [reinterpretation], and,
in my opinion, in the future, this could [change to]
performing a completely new test, instead of
reconsidering old data.” (Participant 11).
Therefore, we recommend that the discussion on re-
interpretation in case no genetic diagnosis was made in-
cludes the comparison in (cost) efficiency between
reinterpretation of previously detected variants, reanaly-
sis of existing data, and redoing genetic tests (i.e. rese-
quencing) based on the latest technologies. To better
determine which genes are of interest for reanalysis or a
new test, laboratories need to have optimal, recently up-
dated information regarding patient and family pheno-
types. For this, continuous feedback is needed from
clinicians and patients. Currently, delivery of phenotypic
information to the laboratory is considered too brief and
unsystematic to reach this goal. Presently, no digital
Table 3 Current practice in communication of reclassified
variants from laboratory to clinician
Reclassificatsion
B (1) LB (2) VUS (3) LP (4) P (5)
Initial classification B (1) NO Varies YES YES
LB (2) NO Varies YES YES
VUS (3) Varies Varies YES YES
LP (4) YES YES YES YES
P (5) YES YES YES Varies
Variants are shown with their initial classification and after reclassification,
ranging from class 1 to class 5 (representing benign, likely benign, variant of
uncertain significance, likely pathogenic, and pathogenic)
Yes - This type of reclassification is communicated from laboratory to clinician
No - This type of reclassification is not communicated from laboratory
to clinician
Varies - Communication of this type of reclassification from laboratory to
clinician varies between laboratory geneticists
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systems are in place to aid in the continuous updating of
phenotypic data, before, during, or after the (initial) test.
Electronic patient records could help update patient and
family phenotypes in a standardized manner, for in-
stance using Human Phenotype Ontology (HPO) or
SNOMED CT terminology. Personal health records,
which enable patients to digitally manage and update
their own medical and family data, could also serve as
an important tool in this context [3].
How are reclassifications perceived and how might this
affect laboratory practice?
A final topic raised during the focus group discussion
that warrants further investigation in future research is
how reclassifications are perceived by laboratory geneti-
cists. For example, are they viewed as the correction of
an error that was made in the initial classification or
merely as inevitable progression of knowledge? The way
reclassifications are perceived may shape the actions
taken by laboratory geneticists and their (legal) responsi-
bilities regarding reinterpretation and reclassification of
variants. For instance, the degree to which laboratory ge-
neticists need to keep up with evolving evidence on vari-
ants within scientific literature.
“If the classification is downgraded, then immediate
contact (…) must be sought with the referring clinician,
because it possibly concerns a calamity, comparable to
entirely missing a mutation. (…) I [mean]
downgrading of [a class] 5 [variant to a class] 3
[variant]. Of course, [downgrading of a class] 3
[variant to a class] 1 [variant] is not a calamity but
rather an insight. [ …] When you miss a mutation, you
have made an error, and [this is] also [the case] when
you classify [a variant] too high.” (Participant 8).
A United States court case (Williams vs Quest/
Athena1), currently in progress, illustrates this issue.
Here, a mother (Williams) claims that a genetic mis-
classification led doctors to administer a pharmaceutical
treatment that worsened her son’s condition and caused
his death (aged 2, due to an epileptic seizure). A genetic
test had been performed in 2007 which had identified a
variant in SCN1A, a gene implicated in Dravet syn-
drome. The variant was classified by the laboratory as a
VUS and therefore did not affect clinical-decision mak-
ing by the boy’s clinicians. Two research papers, avail-
able publicly at the time of the laboratory report, already
stated that this presumed VUS was probably a patho-
genic variant. In 2015, the laboratory issued a new report
with the variant reclassified as known to be disease caus-
ing. The prosecution argues that the initial report con-
tained a mistaken classification and that had this variant
been “correctly” classified in 2007, thereby pointing to
the diagnosis of Dravet syndrome, different medication
would have been given to the child and the fatal seizure
would not have occurred [13]. This case raises important
questions in the context of variant reclassification. Are
reclassifications a correction of a previously made mis-
take (i.e. the initial classification) in some cases and
should laboratory geneticists be held liable for making it,
if the knowledge suggesting an alternate classification
was available at first interpretation or even afterwards?
A factor complicating the question of error, such as in
the Williams vs Quest/Athena case, is that there is no
gold standard regarding what is considered to be enough
evidence for an initial classification or for a reclassifica-
tion. It is not simply a question of whether the evidence
for making a certain classification was there and whether
it was adequately taken into account. As discussed earl-
ier (Introduction), the amount of evidence needed differs
for different conditions and variant types, and what is
considered sufficient evidence for a certain variant clas-
sification differs between laboratory geneticists. As such,
it may be difficult to establish at what point the act of
making an initial classification should stray into the ter-
ritory of error.
Yet, some reclassifications may more likely be consid-
ered by laboratory geneticists as the correction of an
error in initial classification than others. In the public
database ClinVar, variants that used to have a seemingly
clear pathogenic or benign classification are currently re-
classified or conflicting interpretations are mentioned
[20, 28]. This means that in rare cases it is possible that
during reinterpretation, pathogenic variants are reclassi-
fied to for instance VUS. When a result is initially re-
ported to be pathogenic, reclassification means that
confidence regarding its pathogenicity had been unwar-
ranted. Whereas when a result is reported as a VUS, it is
implicit that there is currently not sufficient evidence
available, but that additional evidence may be obtained
in the future, thereby inherently subjecting this variant
to possible future reclassification.
We suggest that, rather than considering pathogenic
down-classifications or benign up-classifications as con-
stituting an event that was not supposed to happen (i.e.
an error), perhaps an increase in awareness is needed
that classifications are not necessarily as fixed as they
might seem. Currently, this awareness mainly exists for
VUS: VUS are expected to change at some point in the
future. However, almost all variants are continuously
subject to reinterpretation and reclassification. When
1The authors do not aim to express any statements or opinions
regarding this individual case. Many of its details are inaccessible to
the public and more issues are involved in this case than are discussed
in this paper. The case is strictly used to highlight the significance and
complexity of certain questions regarding reclassification in practice
and to stimulate discussion.
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considering trends on reclassification, it has been shown
that progression of information on variants often leads
to a shift towards conflicting interpretations of patho-
genicity, rather than to more clear and correct classifica-
tions [28]. This emphasizes the argument that both
initial and reclassifications should be inherently consid-
ered as subject to possible change. This does not imply,
however, that clinical decisions such as initiating cascade
family screening on presumed pathogenic variants
should be abolished, based on the argument that one
cannot be fully certain that these variants are as patho-
genic as we currently think they are. Rather, both health-
care professionals and patients need to be cognizant that
evolving knowledge is intrinsic to genetics and that,
therefore, changes in a patient’s diagnosis or genetic risk
profile are a possibility with increasing knowledge.
Conclusion
For professionals within clinical genetics laboratories,
challenges exist concerning the daily practice of reinter-
pretation and reclassification of genetic variants, as well as
its downstream effects, such as issuing new reports to rele-
vant clinicians. Based on issues noted by representatives
from all (nine) Dutch clinical molecular genetics diagnos-
tic laboratories, discrepant practices between laboratory
geneticists, and current literature, we have formulated and
discussed five challenging questions for daily laboratory
practice that need to be addressed in the process of creat-
ing and refining guidelines: 1) Should active reinterpret-
ation of variants be conducted by the laboratory as a
routine practice?; 2) How does reinterpretation initiated
by the laboratory relate to patient expectations and con-
sent?; 3) When should reinterpreted data be considered
clinically significant and communicated from laboratory
to clinician?; 4) Should reinterpretation, reanalysis or a
new test be conducted?; 5) How are reclassifications
perceived and how might this affect laboratory practice?
This study shows the importance of looking at laboratory
practice and perceptions to identify relevant input for policy
and guideline discussions, as well as future research, in the
context of managing the changing nature of genetic data.
The laboratories in our study reinterpret genetic variants re-
actively, mainly due to a request by a clinician or upon iden-
tification of a previously classified variant in a new patient.
This is in line with international guidelines that place no re-
sponsibility on laboratories to actively reinterpret genetic
data [4, 18]. However, in practice, the topic of how active
the laboratory’s role should be in initiating reinterpretation
of genetic information and what this would imply for discus-
sions on patient autonomy appeared to be a salient one for
laboratory geneticists, with differing opinions on desirability
and one laboratory investigating how to implement active,
periodic reinterpretation in their practice. Furthermore, our
study demonstrates that laboratory geneticists are concerned
with the efficacy of patient consent procedures, the emo-
tional effect reclassifications (e.g. VUS down-classifications)
might have on patients, and what is defined as clinically sig-
nificant data; issues that have traditionally been attributed to
and investigated within the realm of clinicians and patients.
Understanding these concerns as they occur in laboratory
practice provides important context for creating and imple-
menting policies, not only around reinterpretation, but also
its downstream effects, such as recontacting patients.
This study has a number of important limitations. This
study was carried out with participants from the
Netherlands and in non-commercial, diagnostic labora-
tories only, as commercial laboratories are not certified
to conduct clinical genetic testing in The Netherlands. It
would be interesting to see whether a study with partici-
pants from different contexts, such as a commercial
laboratory setting or other countries, would yield
additional themes and issues.
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